Phio Pharmaceuticals (NASDAQ:PHIO) Shares Up 2.5%

Shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIOGet Free Report) rose 2.5% on Thursday . The stock traded as high as $0.75 and last traded at $0.74. Approximately 10,152 shares were traded during trading, a decline of 97% from the average daily volume of 298,217 shares. The stock had previously closed at $0.72.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Phio Pharmaceuticals in a research report on Tuesday, May 14th.

Read Our Latest Report on PHIO

Phio Pharmaceuticals Trading Down 0.7 %

The business has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.78.

Phio Pharmaceuticals (NASDAQ:PHIOGet Free Report) last posted its earnings results on Thursday, May 9th. The company reported ($0.47) EPS for the quarter. Research analysts predict that Phio Pharmaceuticals Corp. will post -1.82 earnings per share for the current fiscal year.

Phio Pharmaceuticals Company Profile

(Get Free Report)

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.

Further Reading

Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with's FREE daily email newsletter.